Meeting
2022 ASCO Gastrointestinal Cancers Symposium
Trastuzumab deruxtecan (T-DXd; DS-8201) in patients with HER2–positive advanced gastric or gastroesophageal junction (GEJ) adenocarcinoma: Final overall survival (OS) results from a randomized, multicenter, open-label, phase 2 study (DESTINY-Gastric01).
Authors
Kensei Yamaguchi
The Cancer Institute Hospital of JFCR, Tokyo, Japan
Kensei Yamaguchi , Yung-Jue Bang , Satoru Iwasa , Naotoshi Sugimoto , Min-Hee Ryu , Daisuke Sakai , Hyun Cheol Cheol Chung , Hisato Kawakami , Hiroshi Yabusaki , Jeeyun Lee , Kaku Saito , Yoshinori Kawaguchi , Takahiro Kamio , Akihito Kojima , Masahiro Sugihara , Kohei Shitara
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Poster Session A: Cancers of the Esophagus and Stomach and Other GI Cancers
Track
Esophageal and Gastric Cancer,Other GI Cancer
Sub Track
Other
Clinical Trial Registration Number
NCT03329690
DOI
10.1200/JCO.2022.40.4_suppl.242
Abstract #
242
Poster Bd #
Online Only
Abstract Disclosures
Similar Posters
Poster
2021 ASCO Annual Meeting
Trastuzumab deruxtecan (T-DXd; DS-8201) in patients with HER2-positive advanced gastric or gastroesophageal junction (GEJ) adenocarcinoma: Final overall survival (OS) results from a randomized, multicenter, open-label, phase 2 study (DESTINY-Gastric01).
First Author: Kensei Yamaguchi
Poster
2020 ASCO Virtual Scientific Program
Trastuzumab deruxtecan (T-DXd; DS-8201) in patients with HER2-positive advanced gastric or gastroesophageal junction (GEJ) adenocarcinoma: A randomized, phase II, multicenter, open-label study (DESTINY-Gastric01).
First Author: Kohei Shitara
Poster
2019 Gastrointestinal Cancers Symposium
![A phase II, multicenter, open-label study of [fam-] trastuzumab deruxtecan (DS-8201a) in subjects with HER2-expressing gastric cancer.](https://d201v5jt9ylckg.cloudfront.net/235/14138/168794/168794_poster_pv.jpg)
A phase II, multicenter, open-label study of [fam-] trastuzumab deruxtecan (DS-8201a) in subjects with HER2-expressing gastric cancer.
First Author: Kohei Shitara
Poster
2022 ASCO Gastrointestinal Cancers Symposium
Trastuzumab deruxtecan (T-DXd; DS-8201) in patients (pts) with HER2-expressing metastatic colorectal cancer (mCRC): Final results from a phase 2, multicenter, open-label study (DESTINY-CRC01).
First Author: Takayuki Yoshino